• SABA M. AlJASMI Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 Penang, Malaysia, Department of Pharmacy, Zayed Military Hospital, Abu Dhabi, United Arab Emirates
  • AMER H. KHAN Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 Penang, Malaysia
  • SYED AZHAR SYED SULAIMAN Discipline of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 Penang, Malaysia
  • MIRZA R. BAIG Clinical Pharmacy and Pharmacy Practice Department, Dubai Pharmacy College, Dubai, United Arab Emirates
  • MALIK OBAIDULLAH Drug Regulatory Authority, Ministry of Health Pakistan, Islamabad, Pakistan
  • EMAD A. MAKRAMALLA Department of Pharmacy, Zayed Military Hospital, Abu Dhabi, United Arab Emirates


Objective: This study aimed to measure concordance between different renal function estimates in terms of drug doses and determine the potential significant clinical differences.

Methods: Around one hundred and eighty patients (≥ 18 y) with chronic kidney disease (CKD) were eligible for inclusion in this study. A paired-proportion cohort design was utilized using an artificial intelligence model. CKD patients refined into those who have drugs adjusted for renal function. For superiority of Cockcroft-Gault (CG) vs. modified diet in renal disease (MDRD) guided with references for concordance or discordance of the two equations and determined the dosing tiers of each drug. Validated artificial neural networks (ANN) was one outcome of interest. Variable impacts and performed reassignments were compared to evaluate the factors that affect the accuracy in estimating the kidney function for a better drug dosing.

Results: The best ANN model classified most cases to CG as the best dosing method (79 vs. 72). The probability was 85% and the top performance was slightly above 93%. Creatinine levels and CKD staging were the most important factors in determining the best dosing method of CG versus MDRD. Ideal and actual body weights were second (24%). Whereas drug class or the specific drug was an important third factor (14%).

Conclusion: Among many variables that affect the optimal dosing method, the top three are probably CKD staging, weight, and the drug. The contrasting CKD stages from the different methods can be used to recognize patterns, identify and predict the best dosing tactics in CKD patients.

Keywords: Artificial, Neural networks, Cockcroft-gault, Modification of diet in renal disease, Chronic kidney disease, Clinical response


Download data is not yet available.


1. US Department of Health and Human Services Food and Drug Administration. Guidance for industry: pharmacokinetics in patients with impaired renal function-study design, data analysis, and impact on dosing and labeling; 1998.
2. European Medicines Agency, Committee for Medicinal Products for Human Use. Note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal function; 2004.
3. Zuber K, Liles AM, Davis J. Medication dosing in patients with chronic kidney disease. J Am Acad Physic Assist 2013;26:19-25.
4. Cook AM, Hatton Kolpek J. Augmented renal clearance. Pharmacotherapy 2019;39:346-54.
5. Murali R, Sathyanarayana D, Muthusethupathi MA. Assessment of quality of life in chronic kidney disease patients using the kidney disease quality of life-short form questionnaire in indian population: a community-based study. Asian J Pharm Clin Res 2015;8:271-4.
6. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70.
7. National Kidney Disease Education Program. Chronic kidney disease and drug dosing: information for providers; 2010.
8. Hermsen ED, Maiefski M, Florescu MC, Qiu F, Rupp ME. Comparison of the modification of diet in renal disease and cockcroft gault equations for dosing antimicrobials. Pharmacotherapy 2009;29:649-55.
9. Stevens LA, Nolin TD, Richardson MM, Feldman HI, Lewis JB, Rodby R, et al. Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations. Am J Kidney Dis 2009;54:33-42.
10. Wargo KA, Eiland EH, Hamm W, English TM, Phillippe HM. Comparison of the modification of diet in renal disease and cockcroft-gault equations for antimicrobial dosage adjustments. Ann Pharmacother 2006;40:1248-53.
11. Golik MV, Lawrence KR. Comparison of dosing recommendations for antimicrobial drugs based on two methods for assessing kidney function: cockcroft-gault and modification of diet in renal disease. Pharmacotherapy 2008;28:1125-32.
12. Jennings S, de Lemos ML, Levin A, Murray N. Evaluation of creatinine-based formulas in dosing adjustment of cancer drugs other than carboplatin. J Oncol Pharm Pract 2010;16:113-9.
13. Spruill WJ, Wade WE, Cobb HH. Comparison of estimated glomerular filtration rate with estimated creatinine clearance in the dosing of drugs requiring adjustments in elderly patients with declining renal function. Am J Geriatr Pharmacother 2008;6:15360.
14. Thummel K, Shen D, Isoherranen N. Design and optimization of dosage regimens: pharmacokinetic data. In: Hardman J, Limbird L, Goodman G. (eds). Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 11th ed. McGraw-Hill: New York, NY; 2006.
15. Matzke GR, Dowling T. Dosing concepts in renal dysfunction. In: Murphy JE. ed. Clinical Pharmacokinetics Pocket Reference. 5th ed. American Society of Health-System Pharmacists: Bethesda, MD; 2011.
16. Charpentier G, Riveline JP, Varroud Vial M. Management of drugs affecting blood glucose in diabetic patients with renal failure. Diabetes Metab 2000;26:73-85.
17. Snyder RW, Berns JS. Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease. Semin Dial 2004;17:365-70.
18. Rocha A, Almeida M, Santos J, Carvalho A. Metformin in patients with chronic kidney disease: strengths and weaknesses. J Nephrol 2013;26:55-60.
19. Stabler SN, Ensom MH. Extended-interval aminoglycoside therapy for adult patients with febrile neutropenia: a systematic review. Can J Hosp Pharm 2011;64:182-91.
20. Jenh AM, Tamma PD, Milstone AM. Extended-interval aminoglycoside dosing in pediatrics. Pediatr Infect Dis J 2011;30:338-9.
21. Habayeb H, Grundy C, Rangaiah J, Van de Velde S. Continuous beta-lactam intravenous antibiotic infusions for outpatient parenteral antimicrobial therapy. Int J Antimicrob Agents 2018;52:436-7.
22. Falagas ME, Vardakas KZ. Continuous or extended intravenous administration of ?-lactam antibiotics. Am J Respir Crit Care Med 2017;195:1077-8.
23. Saadah LM, Chedid FD, Sohail MR, Nazzal YM, Al Kaabi MR, Rahmani AY. Palivizumab prophylaxis during nosocomial outbreaks of the respiratory syncytial virus in a neonatal intensive care unit: predicting effectiveness with an artificial neural network model. Pharmacotherapy 2014;34:251-9.
24. Tulloh R, Medrano Lopez C, Checchia PA, Stapper C, Sumitomo N, Gorenflo M, et al. CHD and respiratory syncytial virus: global expert exchange recommendations. Cardiol Young 2017;27:1504-21.
25. Adult drug book–kidney disease program. Available from: [Last accessed on 13 Jun 2018]
26. European Medicines Agency. Available from: [Last accessed on 24 Mar 2019.
27. HAAD list of approved medications. Available from: [Last accessed on 08 Jun 2018].
28. Leibovici L, Yahav D, Paul M. Excess mortality related to cefepime. Lancet Infect Dis 2010;10:293-4.
29. Desrochers JF, Lemieux JP, Morin Belanger C, Paradis FS, Lord A, Bell R, et al. Development and validation of the PAIR (Pharmacotherapy Assessment in Chronic Renal Disease) criteria to assess medication safety and use issues in patients with CKD. Am J Kidney Dis 2011;58:527-35.
30. Pourrat X, Sipert AS, Gatault P, Sautenet B, Hay N, Guinard F, et al. Community pharmacist intervention in patients with renal impairment. Int J Clin Pharm 2015;37:1172-9.
31. Glatard A, Bourguignon L, Jelliffe RW, Maire P, Neely MN, Goutelle S. Influence of renal function estimation on pharmacokinetic modeling of vancomycin in elderly patients. Antimicrob Agents Chemother 2015;59:2986-94.
32. Dooley MJ, Poole SG, Rischin D. Dosing of cytotoxic chemotherapy: impact of renal function estimates on the dose. Ann Oncol 2013;24:2746-52.
33. Diego del Río E, Soy Muner D, Gratacos Santanach L, Ribas Sala J. The impact of different renal function measuring methods on the dosages of meropenem, piperacillin/tazobactam and cefepime in critically ill patients. Farm Hosp 2008;32:199-207.
34. Breton G, Froissart M, Janus N, Launay Vacher V, Berr C, Tzourio C, et al. Inappropriate drug use and mortality in community-dwelling elderly with impaired kidney function-the three–city population-based study. Nephrol Dial Transplant 2011;26:2852-9.
35. Lascano ME, Poggio ED. Kidney function assessment by creatinine-based estimation equations. Available from:–function/. [Last accessed 11 Jan 2018]
36. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
37. Jones GRD. Estimating renal function for drug dosing decisions. Clin Biochem Rev 2011;32:81-8.
38. Karsch Volk M, Schmid E, Wagenpfeil S, Linde K, Heemann U, Schneider A. Kidney function and clinical recommendations of drug dose adjustment in geriatric patients. BMC Geriatr 2013;13:92–9.
39. Dersch D, McCormack J. Estimating renal function for drug dosing: rewriting the gospel? Can J Hosp Pharm 2008; 61:138-43.
98 Views | 22 Downloads
How to Cite
AlJASMI, S. M., A. H. KHAN, S. A. S. SULAIMAN, M. R. BAIG, M. OBAIDULLAH, and E. A. MAKRAMALLA. “VARIABLES IMPACTING GFR ESTIMATION METHOD FOR DRUG DOSING IN CKD: ARTIFICIAL NEURAL NETWORK PREDICTION MODEL”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 11, no. 12, Dec. 2019, pp. 5-9, doi:10.22159/ijpps.2019v11i12.35688.
Original Article(s)